Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease
TRANSCEND-CKD is designed to provide mechanistic insights on the effects of retatrutide on kidney function and structure, and to inform clinical findings in the ongoing cardio-kidney outcome trial TRIUMPH-Outcomes (NCT06383390).
Authors
- Zvonko Miličević
- Hiddo J.L. Heerspink (ORCID: https://orcid.org/0000-0002-3126-3730)
- Petter Bjornstad (ORCID: https://orcid.org/0000-0002-5160-2947)
- Lisette Koeneman
- Daniël H. van Raalte (ORCID: https://orcid.org/0000-0003-2894-6124)
- Ilke Tunali
- Mathijs C. Bunck
- Po-Chang Wu
Institutions
- University Medical Center Groningen (NL)
- Eli Lilly (United States) (US)
- University of Groningen (NL)
- University of Washington (US)
- Somerset Medical Center (US)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1093/ndt/gfaf230
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company